The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.
Igal Kushnir(Tel Aviv University), M. Neil Reaume(The University of Melbourne), Michael Ong(Ottawa Hospital), Elham Sabri(Ottawa Hospital), Kim Koczka(University of Ottawa), Christina M. Canil(University of Ottawa)
Cited by 2
Related Papers
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Age of Transfused Blood in Critically Ill Adults
|New England Journal of Medicine|2015|559
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
|The Lancet Oncology|2023|195
Soy, Red Clover, and Isoflavones and Breast Cancer: A Systematic Review
|PLoS ONE|2013|189